Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.
Previous close
$1.81
+$0.13 · +7.74%
Regular session · ET · Market data may be delayed.
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.
Day range
Current $1.81
52-week range
Current $1.81
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
36
Expensive
Sentiment
72
Bullish
Risk
71
High Risk
Momentum
65
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.
Day range
Current $1.81
52-week range
Current $1.81
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 13.86M USD | 16.15M USD | — | — | — |
| Cost of goods sold | 2.39M USD | 475K USD | — | — | — |
| Gross profit | 11.47M USD | 15.67M USD | — | — | — |
| Research and development | 73.7M USD | 58.75M USD | 49.59M USD | 86.13M USD | 51.05M USD |
| Selling, general, and administrative | 22.19M USD | 25.42M USD | 32.61M USD | 37.35M USD | 18.66M USD |
| Operating expenses | 95.89M USD | 105.13M USD | 82.2M USD | 123.48M USD | 69.72M USD |
| Interest income | 3.61M USD | 7.04M USD | 6.63M USD | 2.76M USD | 23K USD |
| Depreciation and amortization | 4.51M USD | 2.98M USD | 1.93M USD | 709K USD | 647K USD |
| Operating income | −84.42M USD | −89.46M USD | −82.2M USD | −123.48M USD | −69.72M USD |
| Net income | −79.62M USD | −77.33M USD | −73.79M USD | −120.72M USD | −75.98M USD |
Company facts updated Nov 22, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$7.00
286.74% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI4.87M0.00%689.3B USD0.03%$340.02-3.52%
Vanguard Extended Market ETFVXF1.25M0.00%30.2B USD0.05%$211.44-3.21%
iShares Biotechnology ETFIBB957.29K0.01%10.53B USD0.44%$199.54-2.05%
iShares Micro-Cap ETFIWC264.77K0.02%1.09B USD0.60%$157.87-3.19%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM250K0.25%99.07M USD0.73%$13.73-3.58%
Invesco Nasdaq Biotechnology ETFIBBQ11.72K0.01%124.07M USD0.19%$33.53-1.70%
ProShares Ultra Nasdaq BiotechnologyBIB6.34K0.01%90.33M USD1.17%$51.43-3.15%
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Biotechnology ETFIBB
iShares Micro-Cap ETFIWC
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM
Invesco Nasdaq Biotechnology ETFIBBQ
ProShares Ultra Nasdaq BiotechnologyBIBAI-generated and delayed market data for informational and educational purposes only. Not investment advice.